BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nagase H, Yamamoto N, Yata M, Ohrui S, Okada T, Saitoh T, Kutsumura N, Nagumo Y, Irukayama-tomobe Y, Ishikawa Y, Ogawa Y, Hirayama S, Kuroda D, Watanabe Y, Gouda H, Yanagisawa M. Design and Synthesis of Potent and Highly Selective Orexin 1 Receptor Antagonists with a Morphinan Skeleton and Their Pharmacologies. J Med Chem 2017;60:1018-40. [DOI: 10.1021/acs.jmedchem.6b01418] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Mondal S, Malakar S. Synthesis of sulfonamide and their synthetic and therapeutic applications: Recent advances. Tetrahedron 2020;76:131662. [DOI: 10.1016/j.tet.2020.131662] [Cited by in Crossref: 14] [Cited by in F6Publishing: 1] [Article Influence: 7.0] [Reference Citation Analysis]
2 Boss C, Roch C. Orexin research: patent news from 2016. Expert Opinion on Therapeutic Patents 2017;27:1123-33. [DOI: 10.1080/13543776.2017.1344221] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
3 Futamura A, Nozawa D, Araki Y, Tamura Y, Tokura S, Kawamoto H, Tokumaru Y, Kakihara S, Aoki T, Ohtake N. Identification of highly selective and potent orexin receptor 1 antagonists derived from a dual orexin receptor 1/2 antagonist based on the structural framework of pyrazoylethylbenzamide. Bioorganic & Medicinal Chemistry 2017;25:5203-15. [DOI: 10.1016/j.bmc.2017.07.051] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
4 Katoh K, Kutsumura N, Yamamoto N, Nagumo Y, Saitoh T, Ishikawa Y, Irukayama-Tomobe Y, Tanimura R, Yanagisawa M, Nagase H. Essential structure of orexin 1 receptor antagonist YNT-707: Conversion of the 16-cyclopropylmethyl group to the 16-sulfonamide group in D-nor-nalfurafine derivatives. Bioorg Med Chem Lett 2022;:128550. [PMID: 35041942 DOI: 10.1016/j.bmcl.2022.128550] [Reference Citation Analysis]
5 Saitoh T, Seki K, Nakajima R, Yamamoto N, Kutsumura N, Nagumo Y, Irukayama-Tomobe Y, Ogawa Y, Ishikawa Y, Yanagisawa M, Nagase H. Essential structure of orexin 1 receptor antagonist YNT-707, part V: Structure-activity relationship study of the substituents on the 17-amino group. Bioorg Med Chem Lett 2020;30:126893. [PMID: 31879208 DOI: 10.1016/j.bmcl.2019.126893] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Ohrui S, Yamamoto N, Saitoh T, Kutsumura N, Nagumo Y, Irukayama-tomobe Y, Ogawa Y, Ishikawa Y, Watanabe Y, Hayakawa D, Gouda H, Yanagisawa M, Nagase H. Essential structure of orexin 1 receptor antagonist YNT-707, Part II: Drastic effect of the 14-hydroxy group on the orexin 1 receptor antagonistic activity. Bioorganic & Medicinal Chemistry Letters 2018;28:774-7. [DOI: 10.1016/j.bmcl.2017.12.069] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
7 Bodnar RJ. Endogenous opiates and behavior: 2017. Peptides 2020;124:170223. [DOI: 10.1016/j.peptides.2019.170223] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
8 Yamamoto N, Ohrui S, Okada T, Yata M, Saitoh T, Kutsumura N, Nagumo Y, Irukayama-tomobe Y, Ogawa Y, Ishikawa Y, Watanabe Y, Hayakawa D, Gouda H, Yanagisawa M, Nagase H. Essential structure of orexin 1 receptor antagonist YNT-707, Part I: Role of the 4,5-epoxy ring for binding with orexin 1 receptor. Bioorganic & Medicinal Chemistry Letters 2017;27:4176-9. [DOI: 10.1016/j.bmcl.2017.07.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
9 Yamamoto N, Ohrui S, Okada T, Saitoh T, Kutsumura N, Nagumo Y, Irukayama-tomobe Y, Ogawa Y, Ishikawa Y, Watanabe Y, Hayakawa D, Gouda H, Yanagisawa M, Nagase H. Essential structure of orexin 1 receptor antagonist YNT-707, part III: Role of the 14-hydroxy and the 3-methoxy groups in antagonistic activity toward the orexin 1 receptor in YNT-707 derivatives lacking the 4,5-epoxy ring. Bioorganic & Medicinal Chemistry 2019;27:1747-58. [DOI: 10.1016/j.bmc.2019.03.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
10 Dale NC, Hoyer D, Jacobson LH, Pfleger KDG, Johnstone EKM. Orexin Signaling: A Complex, Multifaceted Process. Front Cell Neurosci 2022;16:812359. [DOI: 10.3389/fncel.2022.812359] [Reference Citation Analysis]
11 Nagumo Y, Katoh K, Iio K, Saitoh T, Kutsumura N, Yamamoto N, Ishikawa Y, Irukayama-Tomobe Y, Ogawa Y, Baba T, Tanimura R, Yanagisawa M, Nagase H. Discovery of attenuation effect of orexin 1 receptor to aversion of nalfurafine: Synthesis and evaluation of D-nor-nalfurafine derivatives and analyses of the three active conformations of nalfurafine. Bioorg Med Chem Lett 2020;30:127360. [PMID: 32738987 DOI: 10.1016/j.bmcl.2020.127360] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Kutsumura N, Koyama Y, Suzuki Y, Tominaga KI, Yamamoto N, Saitoh T, Nagumo Y, Nagase H. Favorskii-Type Rearrangement of the 4,5-Epoxymorphinan Skeleton. Org Lett 2018;20:1559-62. [PMID: 29513016 DOI: 10.1021/acs.orglett.8b00288] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
13 He Y, Zheng Z, Liu Q, Song G, Sun N, Chai X. Tunable Synthesis of 2-Ene-1,4-diones, 4-Hydroxycyclopent-2-en-1-ones, and 2-(Furan-3-yl)acetamides via Palladium-Catalyzed Cascade Reactions of Allenols. J Org Chem 2018;83:12514-26. [PMID: 30239199 DOI: 10.1021/acs.joc.8b01753] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Tanguturi P, Pathak V, Zhang S, Moukha-Chafiq O, Augelli-Szafran CE, Streicher JM. Discovery of Novel Delta Opioid Receptor (DOR) Inverse Agonist and Irreversible (Non-Competitive) Antagonists. Molecules 2021;26:6693. [PMID: 34771099 DOI: 10.3390/molecules26216693] [Reference Citation Analysis]
15 Herring WJ, Roth T, Krystal AD, Michelson D. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications. J Sleep Res 2018;28. [DOI: 10.1111/jsr.12782] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
16 Perrey DA, Zhang Y. Therapeutics development for addiction: Orexin-1 receptor antagonists. Brain Res 2020;1731:145922. [PMID: 30148984 DOI: 10.1016/j.brainres.2018.08.025] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
17 Watanabe H, Fukui K, Shimizu Y, Idoko Y, Nakamoto Y, Togashi K, Saji H, Ono M. Synthesis and biological evaluation of F-18 labeled tetrahydroisoquinoline derivatives targeting orexin 1 receptor. Bioorganic & Medicinal Chemistry Letters 2019;29:1620-3. [DOI: 10.1016/j.bmcl.2019.04.044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
18 Hirayama S, Iwai T, Higashi E, Nakamura M, Iwamatsu C, Itoh K, Nemoto T, Tanabe M, Fujii H. Discovery of δ Opioid Receptor Full Inverse Agonists and Their Effects on Restraint Stress-Induced Cognitive Impairment in Mice. ACS Chem Neurosci 2019;10:2237-42. [DOI: 10.1021/acschemneuro.9b00067] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
19 Katoh K, Yamamoto N, Ishikawa Y, Irukayama-Tomobe Y, Tanimura R, Saitoh T, Nagumo Y, Kutsumura N, Yanagisawa M, Nagase H. Effect of removal of the 14-hydroxy group on the affinity of the 4,5-epoxymorphinan derivatives for orexin and opioid receptors. Bioorg Med Chem Lett 2022;:128527. [PMID: 35007722 DOI: 10.1016/j.bmcl.2022.128527] [Reference Citation Analysis]
20 Saitoh T, Seki K, Nakajima R, Yamamoto N, Kutsumura N, Nagumo Y, Irukayama-Tomobe Y, Ogawa Y, Ishikawa Y, Tanimura R, Yanagisawa M, Nagase H. Essential structure of orexin 1 receptor antagonist YNT-707, Part IV: The role of D-ring in 4,5-epoxymorphinan on the orexin 1 receptor antagonistic activity. Bioorg Med Chem Lett 2019;29:2655-8. [PMID: 31375290 DOI: 10.1016/j.bmcl.2019.07.039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]